Benitec Biopharma Inc. Cash
Benitec Biopharma Inc. (BNTC) had Cash of $98.60 million as of 2026-03-31, per its 10-Q filed 2026-05-14.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments › Cash and Cash Equivalent
us-gaap:Cash · last filed 2026-05-14
- 2026-03-31: Cash $98.60M.
- 2025-12-31: Cash $98.20M.
- 2025-09-30: Cash $72.80M.
- 2025-06-30: Cash $72.80M.
| Period end | Cash |
|---|---|
| 2026-03-31 | $98.60M 10-Q · filed 2026-05-14 |
| 2025-12-31 | $98.20M 10-Q · filed 2026-02-12 |
| 2025-09-30 | $72.80M 10-Q · filed 2025-11-14 |
| 2025-06-30 | $72.80M 10-K/A · filed 2026-03-20 |
| 2025-03-31 | $70.20M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $39.50M 10-Q · filed 2025-02-14 |
| 2024-09-30 | $21.70M 10-Q · filed 2024-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |